Echo findings in heart failure patients with preserved or mildly reduced ejection fraction treated with an atrial shunt shed light on why only certain patients respond to therapy.
The Class I recall stems from reports of increased resistance in the guidewire handle and chamber during use, which could cause injury to the blood vessel walls.
Edwards Lifesciences received approval for its Evoque tricuspid valve replacement system, the first transcatheter therapy approved in the US for tricuspid regurgitation.
The proposal by the major cardiovascular societies to form a new certification board represents a revolution in the field of CME and assessment of competency. What is known so far?